ANNEX IV
CONCLUSIONS ON THE GRANTING OF THE MARKETING AUTHORISATION UNDER
EXCEPTIONAL CIRCUMSTANCES AND PRESENTED BY THE EUROPEAN MEDICINES
AGENCY
1
Conclusions presented by the European Medicines Agency on:
ï‚· Marketing authorisation under exceptional circumstances
The CHMP having considered the application is of the opinion that the risk-benefit balance is 
favourable to recommend the granting of the marketing authorisation under exceptional circumstances 
as further explained in the European Public Assessment Report.
2
